Brain tumour
A study to compare tyrosine kinase inhibitor versus tyrosine kinase inhibitor with intrathecal methotrexate in lung cancer patients with brain metastasis
Who can joinWomen
AgeAsk the trial team
Kind of studyStudy of how care is given
What it testsSupport or lifestyle care
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Last updated on the registry 13 Oct 2025. Please confirm with the hospital that this trial is still taking patients.
Contact hospital
The registry names this hospital as the trial's main contact. Ask them which hospitals are taking patients.
Tata Memorial CenterMumbaiDirections ↗
Registry summary (technical)
A randomized controlled study comparing tyrosine kinase inhibitor versus tyrosine kinase inhibitor with intrathecal methotrexate in leptomeningeal carcinomatosis in driver mutated non-small cell lung carcinoma - TYKME
Sponsor: Tata Memorial Hospital
CTRI/2022/01/039501 on CTRI, India's trial registry
Source: Clinical Trials Registry – India (CTRI), via WHO ICTRP, data of 12 Oct 2026
Last updated on the registry 13 Oct 2025 · read by us 5 Nov 2026